Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03790488
Recruitment Status : Recruiting
First Posted : December 31, 2018
Last Update Posted : December 31, 2018
Sponsor:
Information provided by (Responsible Party):
Jounce Therapeutics, Inc.

Brief Summary:
JTX-4014-101 is a Phase 1, open label, dose escalation clinical study of JTX-4014 in adult subjects with advanced refractory solid tumor malignancies, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D).

Condition or disease Intervention/treatment Phase
Cancer Drug: JTX-4014 Phase 1

Detailed Description:
JTX-4014 is a fully human IgG4 monoclonal antibody designed to specifically bind to PD-1 and block its interaction with its ligands, PD-L1 and PD-L2, to augment anti-tumor T cell activity. This is a Phase 1, first in human, open label, multicenter, dose escalation clinical study to evaluate the safety, tolerability, and PK of JTX-4014 when administered as a single agent to adult subjects with advanced refractory solid tumor malignancies. The intent of this study will be to determine the MTD and RP2D.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1 First in Human Study of Programmed Cell Death Receptor-1 (PD-1) Inhibitor Monoclonal Antibody (mAb) JTX-4014 in Adult Subjects With Advanced Refractory Solid Tumor Malignancies
Actual Study Start Date : December 6, 2018
Estimated Primary Completion Date : September 2019
Estimated Study Completion Date : December 2020

Arm Intervention/treatment
Experimental: JTX-4014
Phase 1 dose escalation of PD-1 inhibitor mAb JTX-4014 by intravenous infusion
Drug: JTX-4014
Specified dose on specified days
Other Name: PD-1 Inhibitor




Primary Outcome Measures :
  1. % subjects with adverse events (AEs) [ Time Frame: Approximately 12 months ]
  2. % subjects with serious adverse events (SAEs) [ Time Frame: Approximately 12 months ]
  3. % subjects with dose-limiting toxicities (DLTs) [ Time Frame: Approximately 12 months ]
  4. % subjects with changes from baseline in pro-inflammatory cytokines [ Time Frame: Approximately 12 months ]
  5. % subjects with clinically significant change from baseline in clinical laboratory tests [ Time Frame: Approximately 12 months ]
  6. Maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of JTX-4014 [ Time Frame: Approximately 12 months ]

Secondary Outcome Measures :
  1. Maximum measured concentration in serum (Cmax) [ Time Frame: Approximately 12 months ]
  2. Time from dosing to Cmax (Tmax) [ Time Frame: Approximately 12 months ]
  3. Area under the serum concentration-time curve (AUC) [ Time Frame: Approximately 12 months ]
  4. Last measurable concentration (Clast) [ Time Frame: Approximately 12 months ]
  5. Time to last measurable concentration (Tlast) [ Time Frame: Approximately 12 months ]
  6. Terminal half-life (t1/2) [ Time Frame: Approximately 12 months ]
  7. Accumulation ratio of JTX-4014 [ Time Frame: Approximately 12 months ]
  8. Evaluate anti-drug antibodies (ADA) against JTX-4014 [ Time Frame: Approximately 12 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Able and willing to participate and comply with all study requirements and provide signed and dated informed consent prior to initiation of any study procedures;
  2. Histologically or cytologically confirmed extracranial solid tumor malignancy that is recurrent, metastatic, or persistent after at least 1 line of standard therapy and with no further standard treatment options that are likely to provide meaningful clinical benefit;
  3. Evaluable or measurable disease, according to the RECIST version 1.1, that has objectively progressed since (or on) previous treatment as assessed by the Investigator; while target lesions are not required, target lesions should be measured if present;
  4. ≥ 18 years of age;
  5. ECOG performance status 0 or 1;
  6. Predicted life expectancy of ≥ 3 months;
  7. Have laboratory values (obtained ≤ 28 days prior to first infusion day) in accordance with the study protocol;
  8. For women of childbearing potential (WOCBP): negative serum pregnancy test within 72 hours prior to planned Cycle 1 Day 1 (C1D1) and a negative urine pregnancy test on C1D1;
  9. WOCBP and males whose partners are WOCBP must agree to use a highly effective method of birth control throughout their participation and for 5 months following the last study drug administration;
  10. Subjects with medical history of the following must be discussed with the Medical Monitor:

    1. Prior biliary tract disorders (as based on hepatobiliary system organ class high level terms of: obstructive bile duct disorders, hepatic vascular disorders, structural and other bile duct disorders).
    2. Portal hypertension and/or hepatic vascular disorders.

Exclusion Criteria:

  1. Concurrent anticancer treatment, either FDA-approved, palliative, or investigational for the cancer being evaluated in this study or for other cancers (with protocol-specified exceptions);
  2. Prior receipt of a PD-1 or PD-L1 inhibitor mAb, including JTX-4014;
  3. The therapies listed below within the specified timeframe or ongoing toxicity attributed to prior therapy that was > Grade 1 according to the NCI CTCAE, with protocol-specified exceptions:

    1. Major surgery < 4 weeks prior to planned C1D1;
    2. Biologic therapy, including non-PD-1/PD-L1 inhibitor immunotherapy, < 28 days prior to planned C1D1;
    3. Chemotherapy < 21 days prior to planned C1D1, or < 42 days for mitomycin or nitrosoureas;
    4. Targeted small molecule therapy < 14 days prior to planned C1D1;
    5. Hormonal or other adjunctive therapy for cancers other than the cancer under evaluation in this study that started < 14 days prior to planned C1D1, with protocol-specified exceptions;
    6. Radiation therapy < 21 days prior to planned C1D1, with protocol-specified exceptions;
    7. Any prior organ transplantation, including allogeneic or autologous stem cell transplantation;
  4. History of intolerance, hypersensitivity, or treatment discontinuation due to severe immune-related adverse events on prior non PD 1/PD L1 inhibitor immunotherapy;
  5. Diagnosis of immunodeficiency, either primary or acquired, or treatment with immunosuppressive levels of systemic corticosteroids or any other form of immunosuppressive therapy within 7 days prior to planned C1D1, with protocol-specified exceptions;
  6. Known severe intolerance or life-threatening hypersensitivity reactions to humanized mAbs or intravenous immunoglobulin preparations; any history of anaphylaxis; prior history of human anti-human antibody response; known allergy to any of the study medications, their analogues, or excipients;
  7. Symptomatic or uncontrolled brain metastases, leptomeningeal disease, or spinal cord compression not definitively treated with surgery or radiation, with protocol-specified exceptions;
  8. Active and clinically relevant bacterial, fungal, or viral infection, including known hepatitis A, B, C, or human immunodeficiency virus;
  9. Receipt of live vaccines within 30 days of planned C1D1;
  10. Women who are pregnant or breastfeeding or who plan to become pregnant/breastfeed while on study; men who plan to father children during the study;
  11. History of pneumonitis requiring treatment with corticosteroids, interstitial lung disease, or severe radiation pneumonitis (excluding localized radiation pneumonitis);
  12. Symptomatic ascites or pleural effusion;
  13. History of acute diverticulitis, intra-abdominal abscess, gastrointestinal obstruction, or abdominal carcinomatosis;
  14. Symptomatic cardiac or cerebrovascular disease that is unresponsive to surgical or medical management;
  15. Medical or social condition that, in the opinion of the Investigator, might place the subject at increased risk, adversely affect compliance, or confound safety or other clinical study data interpretation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03790488


Contacts
Layout table for location contacts
Contact: Gosia Riley JTX-4014-101@jouncetx.com

Locations
Layout table for location information
United States, Colorado
Sarah Cannon Research Institute at HealthONE Recruiting
Denver, Colorado, United States, 80218
Contact: Kari Koga    720-754-4650      
United States, Florida
Florida Cancer Specialists - Sarasota Cattlemen Recruiting
Sarasota, Florida, United States, 34232
Contact: Jill Martin    941-377-9993      
United States, Michigan
START Midwest - Cancer & Hematology Centers of Western Michigan Recruiting
Grand Rapids, Michigan, United States, 49546
Contact: Shannon Skibinski-Preston    616-954-5552      
United States, Texas
South Texas Accelerated Research Therapeutics (START) Recruiting
San Antonio, Texas, United States, 78229
Contact: Carrie Choi    210-593-2574      
Sponsors and Collaborators
Jounce Therapeutics, Inc.
Investigators
Layout table for investigator information
Study Director: Elizabeth Trehu, MD, FACP Jounce Therapeutics, Inc.

Layout table for additonal information
Responsible Party: Jounce Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT03790488     History of Changes
Other Study ID Numbers: JTX-4014-101
First Posted: December 31, 2018    Key Record Dates
Last Update Posted: December 31, 2018
Last Verified: December 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Jounce Therapeutics, Inc.:
Solid Tumor Malignancies
JTX-4014
Monoclonal Antibody (mAb)
Programmed Cell Death Receptor-1 (PD-1)
Immunotherapy
Immuno-oncology
Dose Escalation

Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs